PanOptica, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Mount Arlington NJ United States (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2014
NCT02022540
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

PanOptica, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

pan-90806 (3 trials)

Drugs in Phase 1 Trials (1)

ranibizumab (lucentis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 1)

Macular Degeneration (Phase 2)

Retinal Diseases (Phase 1)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2